Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos
Angiogenesis is a fundamental developmental process and a hallmark of cancer progression. Receptor tyrosine kinases (RTK) are targets for cancer therapy which may include their action as anti-angiogenic agents. Derazantinib (DZB) is an inhibitor of the fibroblast growth factor receptors (FGFRs) 1–3...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2020-12-01
|
| Serie: | Pharmaceuticals |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/1424-8247/14/1/25 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|